Profund Advisors LLC Purchases 21,149 Shares of Celldex Therapeutics, Inc. $CLDX

Profund Advisors LLC boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 99.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 42,454 shares of the biopharmaceutical company’s stock after acquiring an additional 21,149 shares during the period. Profund Advisors LLC’s holdings in Celldex Therapeutics were worth $1,153,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in Celldex Therapeutics by 10.8% in the third quarter. Wellington Management Group LLP now owns 5,800,003 shares of the biopharmaceutical company’s stock worth $150,046,000 after purchasing an additional 567,677 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Celldex Therapeutics by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock valued at $109,384,000 after acquiring an additional 72,817 shares in the last quarter. Bellevue Group AG boosted its stake in Celldex Therapeutics by 7.6% in the 3rd quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock worth $92,037,000 after purchasing an additional 250,100 shares in the last quarter. Commodore Capital LP boosted its stake in Celldex Therapeutics by 7.8% in the 2nd quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock worth $70,208,000 after purchasing an additional 250,000 shares in the last quarter. Finally, Eventide Asset Management LLC grew its position in Celldex Therapeutics by 37.1% during the 3rd quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock worth $48,096,000 after purchasing an additional 502,909 shares during the last quarter.

Celldex Therapeutics Trading Down 1.0%

Shares of NASDAQ:CLDX opened at $30.58 on Friday. Celldex Therapeutics, Inc. has a twelve month low of $18.55 and a twelve month high of $35.79. The company’s 50 day moving average is $32.00 and its 200 day moving average is $28.21. The company has a market cap of $2.40 billion, a PE ratio of -7.18 and a beta of 0.98.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.80 million. Equities research analysts predict that Celldex Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wolfe Research upgraded shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target on the stock in a research note on Monday, March 23rd. Wells Fargo & Company upped their price target on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. The Goldman Sachs Group upped their price target on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Monday, March 2nd. Barclays upped their price target on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, Stifel Nicolaus restated a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $49.78.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.